| 001 | 874917 | ||
| 005 | 20210130004824.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.119.229542 |2 doi |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 024 | 7 | _ | |a 2128/24866 |2 Handle |
| 024 | 7 | _ | |a altmetric:63843334 |2 altmetric |
| 024 | 7 | _ | |a pmid:31324713 |2 pmid |
| 024 | 7 | _ | |a WOS:000512119600013 |2 WOS |
| 037 | _ | _ | |a FZJ-2020-01701 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Dietlein, Felix |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a An 18 F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18 F-JK-PSMA-7 During the First Year of Application |
| 260 | _ | _ | |a New York, NY |c 2020 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1589439556_12063 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a In preclinical trials, the recently developed tracer 2-methoxy-18F-DCFPyL (18F-JK-prostate-specific membrane antigen [PSMA]-7) has shown favorable properties regarding clinical performance and radiochemical accessibility. The aim of this study was to evaluate the clinical utility of 18F-JK-PSMA-7 for PET/CT imaging of patients with prostate cancer. Methods: In an Institutional Review Board–approved pilot study, the initial clinical utility of PET/CT imaging with 18F-JK-PSMA-7 was directly compared with 68Ga-PSMA-11 PET/CT in a group of 10 patients with prostate cancer. The 2 PSMA tracers were administered to each patient less than 3 wk apart. Next, we analyzed the data of 75 consecutive patients who had undergone clinical 18F-JK-PSMA-7 PET/CT imaging for tumor localization of biochemical recurrence (BCR). Results: The pilot study in 10 patients who were examined with both PSMA tracers demonstrated that 18F-JK-PSMA-7 was at least equivalent to 68Ga-PSMA-11. All unequivocally 68Ga-PSMA-11–positive lesions could be also detected using 18F-JK-PSMA-7, and in 4 patients additional suspected PSMA-positive lesions were identified (1 patient changed from PSMA-negative to PSMA-positive). In patients with BCR (after prostatectomy or radiotherapy), the capacity of 18F-JK-PSMA-7 PET/CT to detect at least one PSMA-positive lesion was 84.8%. The prostate-specific antigen (PSA)–stratified detection rate of 18F-JK-PSMA-7 after prostatectomy varied among 54.5% (6/11 patients; PSA < 0.5 μg/L), 87.5% (14/16 patients; PSA 0.5–2 μg/L), and 90.9% (20/22 patients; PSA > 2 μg/L). Conclusion: The tracer 18F-JK-PSMA-7 was found to be safe and clinically useful. We demonstrated that 18F-JK-PSMA-7 was not inferior when directly compared with 68Ga-PSMA-11 in a pilot study but indeed identified additional PSMA-avid suspected lesions in oligometastasized patients with BCR. In a subsequent analysis of a clinical cohort of BCR patients, 18F-JK-PSMA-7 was useful in tumor localization. 18F-JK-PSMA-7 is recommended for future prospective trials. |
| 536 | _ | _ | |a 573 - Neuroimaging (POF3-573) |0 G:(DE-HGF)POF3-573 |c POF3-573 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Hohberg, Melanie |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Kobe, Carsten |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Zlatopolskiy, Boris D. |0 P:(DE-Juel1)176188 |b 3 |u fzj |
| 700 | 1 | _ | |a Krapf, Philipp |0 P:(DE-Juel1)169356 |b 4 |u fzj |
| 700 | 1 | _ | |a Endepols, Heike |0 P:(DE-Juel1)180330 |b 5 |u fzj |
| 700 | 1 | _ | |a Täger, Philipp |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Hammes, Jochen |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Heidenreich, Axel |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 9 |u fzj |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 10 |u fzj |
| 700 | 1 | _ | |a Dietlein, Markus |0 P:(DE-HGF)0 |b 11 |e Corresponding author |
| 773 | _ | _ | |a 10.2967/jnumed.119.229542 |g Vol. 61, no. 2, p. 202 - 209 |0 PERI:(DE-600)2040222-3 |n 2 |p 202 - 209 |t Journal of nuclear medicine |v 61 |y 2020 |x 2159-662X |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/874917/files/J%20Nucl%20Med-2020-Dietlein-202-9-1.pdf |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/874917/files/Autorenmanuskript.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://juser.fz-juelich.de/record/874917/files/Autorenmanuskript.pdf?subformat=pdfa |
| 856 | 4 | _ | |x pdfa |u https://juser.fz-juelich.de/record/874917/files/J%20Nucl%20Med-2020-Dietlein-202-9-1.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:874917 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)176188 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)169356 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)180330 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)166419 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)177611 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-573 |2 G:(DE-HGF)POF3-500 |v Neuroimaging |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
Gast ::